Three-day and five-day decitabine regimen comparative efficacy in myelodysplastic syndrome.
Dudina G.A.,1 Golenkov A.K., Mitina T.A.2
1 Moscow Clinical Scientific and Practical Center;
2 Moscow Regional Clinica Research Institut name of MF Vladimir
The article presents the results of a single-center retrospective clinical study of decitabine efficacy (DNA hypermethylation inhibitor) in 52 patients with MDS using 3-day and 5-day treatment regimens in the context of practical public health. The patients therapy regimen depending analysis showed that the overall survival in patients with low and intermediate MDS risk was 34 months and 30 months in a three-day and a five-day therapy regimen respectively. Whereas in patients with a higher progression risk it was 28 and 12 months, respectively. The overall survival in general for the two groups also differed: 29 months vs 20 months in the 3-day and 5 days regimen respectively. Thus, the probability of the decitabine cumulative dose effect on the survival rates improvement was confirmed. Statistical analysis was performed by Statistica 6.0.
myelodysplastic syndrome, DNA hypermethylation, hypomethylating therapy, decitabine, cumulative dose of the drug.
1. Dick de Vos, Wendy van Overveld. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol (2005) 84; 3-8.
2. Hagop M. Kantarjian, Jean-Pierre J. Issa, Craig S. Rosenfeld et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer, 2006; 106; 1794-80.
3. Hagop M. Kantarjian, Susan O`Brein, Jianqin Shan et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer, 2007; 109: 265-73.
4. Hagop M. Kantarjian, Susan O`Brein, Xuelin Huang, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Cancer, 2007; 109: 1133-7.
5. Schanz J., Tuchler H., Solé F. et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30(8):820-9.
6. Al-Ameri A., Cherry M., Garcia-Manero G., Quintás-Cardama A. Standard therapy for patients with myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2011;11(4):303-13.
7. Kantarjian H., Issa J.P., Rosenfeld C.S. et al. Decitabine improves patientoutcomes in myelodysplastic syndromes. Results of a phase III randomized study. Cancer 2006; 106: 1794-803.
8. Kantarjian H., Oki Y., Garcia-Manero G. et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic
9.Golenkov A.K., Dydina G.A. , i soavt Klinicheskaya effektivnost Dakogena pri mielodisplasticheskom sindrome. Onkogematologiya N4 2008 36-38.
10.Gricaev S.V., Abdylkadirov K.M., Shihbabaeva D.I. i dr. Opit primeneniya dakogena dlya lecheniya bolnih mielodisplasticheskim sindromom i hronicheskim mielomonocitanim leikozom. Onkogematologiya2009; 2: 28-34.1.
12. Bryan J., Kantarjian H., Garcia-Manero G., Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Exp. Opin. Drug Metab. Toxicol. 2011; 7: 661-72.
13. Danilov A.V., Relias V., Feeney D.M., Miller K.B. Decitabine is an effective treatment of idiopathic myelofibrosis. Br. J. Haemat. 2009; 145: 131-46.
14. Saba H.I. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin. Risk Manag. 2007; 3: 807-17.
15. Kantarjian H.M., O?Brien S., Shan J. et al. Update of the decitabine experience
in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007; 109: 265-73.
16.Troy JD, Atallah E, Geyer JT, Saber W. Myelodysplastic syndromes in the United States: an update for clinicians. Ann Med. 2014; 46(5): 283-289.
17. David P. Steensma, Maria R. Baer, James L. Slack, Rena Buckstein, Lucy A. Godley, Guillermo Garcia-Manero,Multicenter Study of Decitabine Administered Daily for 5 Days Every 18 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial Journal of Clinical Oncology 3 Number 23 August 10 2009 3842-48